Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | 28.56% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 09/29/2023 | 74.47% | JP Morgan | $17 → $19 | Maintains | Overweight |
| 07/11/2023 | 37.74% | Morgan Stanley | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight |
| 03/28/2023 | 56.11% | B of A Securities | $16 → $17 | Maintains | Buy |
| 03/02/2023 | 56.11% | UBS | $15 → $17 | Maintains | Buy |
| 03/02/2023 | 1.01% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2023 | 46.92% | BTIG | $14 → $16 | Maintains | Buy |
| 11/08/2022 | 37.74% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 09/09/2022 | 28.56% | Morgan Stanley | → $14 | Initiates Coverage On | → Equal-Weight |
| 02/24/2022 | 28.56% | SVB Leerink | $16 → $14 | Maintains | Outperform |
| 01/14/2022 | 46.92% | SVB Leerink | $12 → $16 | Upgrades | Market Perform → Outperform |
| 01/13/2022 | 37.74% | Cantor Fitzgerald | $16 → $15 | Maintains | Overweight |
| 11/15/2021 | 46.92% | Stifel | $12 → $16 | Upgrades | Hold → Buy |
| 09/30/2021 | 46.92% | JP Morgan | → $16 | Upgrades | Neutral → Overweight |
| 09/30/2021 | 10.19% | SVB Leerink | $13 → $12 | Maintains | Market Perform |
| 05/27/2021 | — | Needham | Initiates Coverage On | → Hold | |
| 05/21/2021 | 46.92% | UBS | → $16 | Initiates Coverage On | → Buy |
| 04/14/2021 | — | Cantor Fitzgerald | Upgrades | Neutral → Overweight | |
| 03/22/2021 | 19.38% | SVB Leerink | $15 → $13 | Maintains | Market Perform |
| 03/02/2021 | 19.38% | Stifel | → $13 | Initiates Coverage On | → Hold |
| 02/12/2021 | 56.11% | Cantor Fitzgerald | $30 → $17 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 74.47% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 37.74% | SVB Leerink | $30 → $15 | Downgrades | Outperform → Market Perform |
| 12/14/2020 | 175.48% | SVB Leerink | $24 → $30 | Maintains | Outperform |
| 11/11/2020 | 92.84% | Berenberg | → $21 | Initiates Coverage On | → Hold |
| 11/06/2020 | 120.39% | SVB Leerink | $19 → $24 | Maintains | Outperform |
| 08/11/2020 | 83.65% | Citigroup | $15 → $20 | Maintains | Buy |
| 06/17/2020 | 74.47% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 02/04/2020 | 83.65% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 01/30/2019 | 83.65% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 01/17/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 12/18/2018 | 65.29% | Guggenheim | → $18 | Initiates Coverage On | → Buy |
| 10/29/2018 | 10.19% | Citigroup | → $12 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月10日 | 28.56% | 摩根士丹利 | $15→$14 | 維護 | 等重 |
| 09/29/2023 | 74.47% | 摩根大通 | $17→$19 | 維護 | 超重 |
| 07/11/2023 | 37.74% | 摩根士丹利 | $15→$15 | 重申 | 等重→等重 |
| 03/28/2023 | 56.11% | B of A證券 | $16→$17 | 維護 | 買 |
| 03/02/2023 | 56.11% | 瑞銀集團 | $15→$17 | 維護 | 買 |
| 03/02/2023 | 1.01% | 高盛 | $10→$11 | 維護 | 中性 |
| 01/18/2023 | 46.92% | BTIG | $14→$16 | 維護 | 買 |
| 11/08/2022 | 37.74% | 摩根士丹利 | $14→$15 | 維護 | 等重 |
| 09/09/2022 | 28.56% | 摩根士丹利 | →$14 | 開始承保 | →等重 |
| 02/24/2022 | 28.56% | SVB Leerink | $16→$14 | 維護 | 跑贏大盤 |
| 2022年01月14日 | 46.92% | SVB Leerink | $12→$16 | 升級 | 市場表現優於→ |
| 2022年01月13日 | 37.74% | 康託·菲茨傑拉德 | $16→$15 | 維護 | 超重 |
| 2021年11月15日 | 46.92% | Stifel | $12→$16 | 升級 | 持有→購買 |
| 09/30/2021 | 46.92% | 摩根大通 | →$16 | 升級 | 中性→超重 |
| 09/30/2021 | 10.19% | SVB Leerink | $13→$12 | 維護 | 市場表現 |
| 2021/05/27 | - | 李約瑟 | 開始承保 | →保留 | |
| 2021/05/21 | 46.92% | 瑞銀集團 | →$16 | 開始承保 | →購買 |
| 04/14/2021 | - | 康託·菲茨傑拉德 | 升級 | 中性→超重 | |
| 03/22/2021 | 19.38% | SVB Leerink | $15→$13 | 維護 | 市場表現 |
| 03/02/2021 | 19.38% | Stifel | →$13 | 開始承保 | →保留 |
| 02/12/2021 | 56.11% | 康託·菲茨傑拉德 | $30→$17 | 評級下調 | 超重→中性 |
| 02/12/2021 | 74.47% | 摩根大通 | →$19 | 評級下調 | 超重→中性 |
| 02/12/2021 | 37.74% | SVB Leerink | $30→$15 | 評級下調 | 跑贏→市場表現 |
| 12/14/2020 | 175.48% | SVB Leerink | $24→$30 | 維護 | 跑贏大盤 |
| 11/11/2020 | 92.84% | 貝倫伯格 | →$21 | 開始承保 | →保留 |
| 11/06/2020 | 120.39% | SVB Leerink | $19→$24 | 維護 | 跑贏大盤 |
| 2020年08月11日 | 83.65% | 花旗集團 | $15→$20 | 維護 | 買 |
| 06/17/2020 | 74.47% | BTIG | →$19 | 開始承保 | →購買 |
| 02/04/2020 | 83.65% | 康託·菲茨傑拉德 | $19→$20 | 假設 | →超重 |
| 2019年05月04日 | - | 詹尼·蒙哥馬利·斯科特 | 開始承保 | →購買 | |
| 2019年01月30日 | 83.65% | 康託·菲茨傑拉德 | →$20 | 開始承保 | →超重 |
| 2019年01月17日 | - | 花旗集團 | 升級 | 中性→購買 | |
| 2018年12月18日 | 65.29% | 古根海姆 | →$18 | 開始承保 | →購買 |
| 2018年10月29日 | 10.19% | 花旗集團 | →$12 | 開始承保 | →中性 |
What is the target price for Amicus Therapeutics (FOLD)?
Amicus Treeutics(Fold)的目標價格是多少？
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by Morgan Stanley on October 10, 2023. The analyst firm set a price target for $14.00 expecting FOLD to rise to within 12 months (a possible 28.56% upside). 8 analyst firms have reported ratings in the last year.
摩根士丹利於2023年10月10日報道了Amicus治療公司(納斯達克：折疊)的最新目標價。這家分析公司將目標價定為14.00美元，預計本益比將在12個月內上升至28.56%。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
Amicus Treeutics(Fold)的最新分析師評級是多少？
The latest analyst rating for Amicus Therapeutics (NASDAQ: FOLD) was provided by Morgan Stanley, and Amicus Therapeutics maintained their equal-weight rating.
友愛治療(納斯達克：折疊)最新分析師評級由摩根士丹利提供，友愛治療維持同等權重評級。
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Amicus Treeutics(Fold)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Amicus Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Amicus治療公司的上一次評級是在2023年10月10日提交的，所以你應該預計下一次評級將在2024年10月10日左右的某個時候提供。
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
分析師對Amicus Treeutics(Fold)的評級正確嗎？
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $15.00 to $14.00. The current price Amicus Therapeutics (FOLD) is trading at is $10.89, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Amicus Treeutics(Fold)評級保持不變，目標價在15.00美元至14.00美元之間。目前Amicus治療公司(Fold)的交易價格為10.89美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。